Description
Mounjaro (tirzepatide)
Mounjaro contains tirzepatide, a prescription medicine used for metabolic disease. In the European Union, it is authorised for improving blood glucose control in type 2 diabetes and also for weight management in certain adults with obesity or overweight-related health problems. This description is based on official product information and published clinical evidence.
Active Ingredient and Medicine Class
The active ingredient is tirzepatide. It is a dual incretin receptor agonist that acts on both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is classified as an antidiabetic medicine and, in some settings, as a medicine for chronic weight management.
Established Medical Uses
Official EU product information states that Mounjaro is used with diet and physical activity to improve glycaemic control in adults with type 2 diabetes. The EMA overview also states that it is used in adults with obesity, or overweight with weight-related health problems, to help reduce and maintain body weight. Clinical studies have shown meaningful reductions in HbA1c and body weight in adults with type 2 diabetes.
How It Works
Tirzepatide mimics two natural gut hormones involved in glucose regulation and appetite control. By activating GIP and GLP-1 receptors, it increases insulin release in response to food, helps lower blood glucose, and reduces appetite.
Important Safety Information
Important cautions in official product information include the risk of low blood glucose when tirzepatide is used with insulin or a sulfonylurea. It should be used with attention to gastrointestinal tolerability. As with other medicines in this class, warnings and precautions are described in the official prescribing information and patient leaflet.
Clinically significant interactions may occur with other glucose-lowering medicines, particularly insulin and sulfonylureas, because of increased hypoglycaemia risk. Treatment decisions and suitability depend on the full medical history and current medicines.
Possible Side Effects
The most commonly reported adverse effects include nausea, vomiting, abdominal pain, constipation and diarrhoea. Low blood glucose is especially reported when tirzepatide is combined with insulin or a sulfonylurea. The EMA notes that these effects were generally mild to moderate and often occurred after dose increases.
Scientific Evidence
Large phase 3 studies in adults with type 2 diabetes showed that tirzepatide improved glycaemic control and produced greater weight reductions than placebo and, in some trials, comparator medicines such as semaglutide or insulin glargine. A peer-reviewed review in PubMed summarised the SURPASS programme and concluded that tirzepatide produced substantial HbA1c lowering and weight loss across the published trials.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, product information, or individual assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA) — Mounjaro: EPAR – Medicine Overview
- Frías et al. — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine (2021)
